Darifenacin: In the treatment of overactive bladder

Drugs and Aging

Volumn 21, Issue 13, 2004, Pages 885-892

  Croom, Katherine F ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; MUSCARINIC M3 RECEPTOR ANTAGONIST; OXYBUTYNIN; TOLTERODINE;

AREA UNDER THE CURVE; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SYMPTOM; TREATMENT INDICATION; URINARY FREQUENCY; URINARY URGENCY; URINE INCONTINENCE; VISUAL IMPAIRMENT; XEROSTOMIA;

ADULT; AGED; AREA UNDER CURVE; BENZOFURANS; BIOLOGICAL AVAILABILITY; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, MUSCARINIC M3; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TREATMENT OUTCOME; URINARY INCONTINENCE;

EID: 8444235987     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421130-00005     Document Type: Review

References (44)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36
4. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurology 2004; 3 (1): 46-53
5. Wallis RM, Burges RA, Cross PE, et al. Darifenacin, a selective muscarinic M-3 antagonist [abstract]. Pharmacol Res 1995; 31 Suppl.: 54
6. Nunn PA, Greengrass PM, Newgreen DT, et al. The binding profile on the novel muscarinic receptor antagonist darifenacin against the five cloned human muscarinic receptors expressed in CHO cells [abstract no. 130P]. Br J Pharmacol 1996 Apr; 117 Suppl.
7. Eglen RM, Pulido-Rios MT, Webber AP, et al. Characterization of the interaction of darifenacin at muscarinic receptor subtypes in vitro [abstract no. 35P]. Br J Pharmacol 1996 Jul; 118 Suppl.
8. Smith CM, Wallis RM. Characterisation of [3H]-darifenacin as a novel radioligand for the study of muscarinic M3 receptors. J Recept Signal Transduct Res 1997; 17 (1-3): 177-84
9. 3 receptor subtype [abstract no. 445]. 32nd Annual Meeting of the International Continence Society; 2002 Aug 27-30; Heidelberg [online]. Available from URL: http://www.icsoffice.org/publications [Accessed 2004 Sep 1]
10. Gillberg PG, Sundquist S, Nilvebrant L. Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol 1998 May 22; 349 (2-3): 285-92
11. Nelson CP, Gupta P, Napier CM, et al. Functional selectivity of muscarinic receptor antagonists for inhibition of M3-mediated phosphoinositide responses in guinea-pig urinary bladder and submandibular salivary gland. J Pharmacol Exp Ther 2004 May 12
12. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004 May 25; 492 (2-3): 243-50
13. Wallis RM, Napier CM. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci 1999; 64 (6-7): 395-401
14. Miyamae K, Yoshida M, Murakami S, et al. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 2003 Dec; 69 (4): 205-11
15. Newgreen DT, Naylor AM. Comparison of the functional muscarinic receptor selectivity of darifenacin with tolterodine and oxybutinin [abstract no. 107P]. Br J Pharmacol 1996 Apr; 117 Suppl.
16. Alexandrou A, Claringbold A, Harris J, et al. Darifenacin has a low affinity for muscarinic M1 receptors in dog saphenous vein confirming its M3 selectivity [abstract no. 458]. Eur Urol Suppl 2003; 1: 117
17. Newgreen DT, Naylor AM. Characterisation of functional muscarinic receptors in human bladder [abstract no. 45P]. Br J Pharmacol 1996 Oct; 119 Suppl.
18. Chua CB, Harriss DR, Marsh KA, et al. Effect of darifenacin on muscarinic responses in normal and unstable human detrusor smooth muscle cells. Neurourol Urodyn 1997; 16: 355-6
19. Williamson IJR, Newgreen DT, Naylor AM. The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat [abstract no. 205P]. Br J Pharmacol 1997 Mar; 120 Suppl.
20. Davies CL, Dodd MG, Merner PA, et al. In vivo bladder selectivity of the novel muscarinic antagonist, darifenacin, in the conscious minipig [abstract no. 202P]. Br J Pharmacol 1996 Apr; 117 Suppl.
21. Mundy AR, Abrams P, Chapple CR, et al. Darifenacin, the first selective M3 antagonist for overactive bladder: comparison with oxybutynin on ambulatory urodynamic monitoring and salivary flow [abstract no. 221]. 31st Annual Meeting of the International Continence Society; 2001 Sep 17-21; Seoul [online]. Available from URL: http://www.icsoffice.org/publications [Accessed 2004 Aug 31]
22. Gupta P, Anderson C, Carter A, et al. In vivo bladder selectivity of darifenacin, a new M3 antimuscarinic agent, in the anesthetised dog [abstract no. 515]. Eur Urol 2002; 1 Suppl 1: 131
23. Newgreen DT, Anderson CWP, Carter TJ, et al. Darifenacin: a novel bladder-selective muscarinic antagonist for the treatment of urge incontinence [abstract no. 1156]. J Urol 1996 May; 155 Suppl.: 600A
24. Matsui M, Motomura D, Karasawa H, et al. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A 2000 Aug 15; 97 (17): 9579-84
25. Kay G. The M3 selective receptor antagonist darifenacin has no clinically relevant effect on cognition and cardiac function [abstract no. 65]. Prog Urol 2004; 14 Suppl. 3: 22
26. Wesnes K, Lipton R, Kolodner K, et al. Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers [abstract no. 513]. 19th Congress of the European Society of Urology; 2004 Mar 24-27; Vienna [online]. Available from URL: http://www.uroweb.org [Accessed 2004 Jun 18]
27. Kerbusch T, Wahlby U, Milligan PA, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol 2003 Dec; 56 (6): 639-52
28. Beaumont KC, Cussans NJ, Nichols DJ, et al. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 1998 Jan; 28 (1): 63-75
29. Data on file. Novartis Pharma AG, 2004 Aug 26
30. Kerbusch T, Milligan PA, Karlsson MO. Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 2004 Feb; 57 (2): 170-80
31. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004 Apr; 45 (4): 420-9; discussion 429
32. Khullar V. Darifenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder [abstract no. 491]. J Urol 2004 Apr; 171 (4 Suppl.): 131
33. Corcos J, Steers W. Efficacy, tolerability and safety of darifenacin given by a flexible titration dosing regimen [abstract no. 178]. Joint Meeting of the International Continence Society and the International Urogynecological Assocation; 2004 Aug 23-27; Paris [online]. Available from URL: http://www.icsoffice.org [Accessed 2004 Jul 2]
34. Cardozo L, Dixon A. Darifenacin prolongs median and minimum warning time associated with urinary urgency [abstract]. Obstet Gynecol 2004 Apr; 103 (4 Suppl.): 130
35. Zinner N, Tuttle J, Marks L. Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist, compared with oxybutynin in the treatment of patients with overactive bladder [abstract no. 378]. Joint Meeting of the International Continence Society and the International Urogynecological Assocation; 2004 Aug 23-27; Paris [online]. Available from URL: http://www.icsoffice.org [Accessed 2004 Jul 2]
36. Chapple CR. Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies [abstract no. 487]. J Urol 2004 Apr; 171 (4 Suppl.): 130
37. Abrams P, Foot J, Lheritier K, et al. Responder rates, a better way to express drug efficacy: data from darifenacin pooled phase III studies [abstract no. 389]. Joint Meeting of the International Continence Society and the International Urogynecological Assocation; 2004 Aug 23-27; Paris [online]. Available from URL: http://www.icsoffice.org [Accessed 2004 Jul 2]
38. Chapple C, Kelleher C, Perrault L. Darifenacin, an M3 selective receptor antagonist, improves quality of life in patients with overactive bladder [abstract no. 67]. Prog Urol 2004; 14 Suppl. 3: 22
39. Glavind K, Perrault L. Patient satisfaction, preference and willingness to reuse darifenacin in the treatment of overactive bladder [abstract no. UP-14.17]. 27th Congress of the Société International d'Urologie; 2004 Oct 3-7; Honolulu [online]. Available from URL: http://www.siu2004.com [Accessed 2004 Sep 30]
40. 3SRA), is effective and well tolerated in elderly patients with overactive bladder [abstract no. P321]. J Am Geriatr Soc 2004 Apr; 52 (4 Suppl.): 126-7
41. Hill S. The effects of darifenacin on the reduction of incontinence episodes in patients with overactive bladder [abstract no. 610]. J Pelvic Med Surg 2004; 10 Suppl. 1
42. Foote J, Glavind K, Kay G. Central nervous system (CNS)-related adverse events in patients with overactive bladder (OAB) treated with darifenacin versus tolterodine [abstract]. 27th Congress of the Société International d'Urologie; 2004 Oct 3-7; Honolulu [online]. Available from URL: http://www.siu2004.com [Accessed 2004 Sep 30]
43. Novartis. Darifenacin increases warning time for OAB sufferers. Media release 2003 Oct 10 [online]. Available from URL: http://www.novartis.com [Accessed 2004 Jun 15]
44. Pharma Times. Novartis' Emselex wins nod for OAB. Media release 2004 Jul 30 [online]. Available from URL: http://www.pharmatimes.com/news/300704e.asp [Accessed 2004 Jul 30]